Alterity Therapeutics (ATHE) Capital Leases (2021 - 2025)

Alterity Therapeutics has reported Capital Leases for 5 years, with the latest figure at -$34305.4 in Q2 2025.

• On a quarterly basis, Capital Leases rose 51.41% year-over-year to -$34305.4 in Q2 2025; TTM through Jun 2025 was -$34305.4, a 51.41% increase from a year earlier, with the FY2025 full-year figure at -$34305.4, up 51.41% from the prior year.
• Capital Leases was -$34305.4 for Q2 2025 at Alterity Therapeutics, up from -$70602.0 in the prior quarter.
• The five-year high for Capital Leases was -$21365.9 in Q2 2021, with the low at -$71632.9 in Q2 2023.
• Average Capital Leases over 5 years is -$47837.2, with a median of -$41280.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Capital Leases tumbled 93.2% in 2022, then soared 51.41% in 2025.
• Over 5 years, Capital Leases stood at -$21365.9 in 2021, then sank by 93.2% to -$41280.0 in 2022, then tumbled by 73.53% to -$71632.9 in 2023, then advanced by 1.44% to -$70602.0 in 2024, then jumped by 51.41% to -$34305.4 in 2025.
• The last three Capital Leases figures came in at -$34305.4 (Q2 2025), -$70602.0 (Q2 2024), and -$71632.9 (Q2 2023), per Business Quant data.